Potential market catalysts in the second quarter of 2018 include top-line clinical trial results for NEOD001 (developed by Prothena) for light-chain (AL) amyloidosis and ALXN1210 (developed by Alexion) for paroxysmal nocturnal haemoglobinuria (PNH), as well as an FDA advisory committee meeting on volanesorsen (developed by Akcea Therapeutics) for familial chylomicronaemia syndrome (FCS)…

Para acessar a publicação na íntegra clique aqui

Fonte: NATURE REVIEWS | DRUG DISCOVERY VOLUME 17 | APRIL 2018 | 233